Abstract
BackgroundNo formal guidelines exist to inform the selection of appropriate equivalence margins or the timing of efficacy assessment for comparative effectiveness trials of biosimilars in rheumatoid arthritis (RA). Studies to...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
